---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-23-037344"
form_type: "8-K"
ticker: null
cik: "0001603207"
company_name: "Notable Labs, Ltd."
filed_at: "2023-10-16T23:59:59+00:00"
generated_at: "2026-06-09T23:21:11.898445+00:00"
event_type: "m_and_a"
sentiment: "neutral"
materiality_score: 1.0
calibrated_materiality_score: 1.0
confidence: "high"
source: SEC EDGAR
---

# Vascular Biogenics completes merger with Notable Labs; former Notable holders own 75.2% of combined co

## Summary
- Former Notable shareholders own ~75.2% of combined co on fully-diluted basis; ~8.94M shares outstanding post-merger.
- 1-for-35 reverse split and name change to Notable Labs, Ltd. effective Oct 16; ticker changes from VBLT to NTBL Oct 17.
- All prior directors resigned; new board appointed: Bock, Feinberg, Galen, Pätsi, Rice, Dubin, Graney. Bock named CEO, McPherson CFO, Wagner CSO.
- Company sold VB-601 asset to Immunewalk for $250k upfront plus up to $4.75M in milestones and royalties.
- New ticker NTBL; CUSIP M7517R107; company now a clinical-stage precision oncology platform.

## SEC filing metadata
- accession: 0001493152-23-037344
- form_type: 8-K
- cik: 0001603207
- company_name: Notable Labs, Ltd.
- filed_at: 2023-10-16T23:59:59+00:00
- event_type: m_and_a
- sentiment: neutral
- materiality_score: 1.0
- calibrated_materiality_score: 1.0
- confidence: high
- sec_items: 2.01, 5.02, 3.03, 5.01, 5.03, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1603207/000149315223037344/0001493152-23-037344-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1603207/000149315223037344/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-23-037344
- JSON: https://secwatch.observer/filing/0001493152-23-037344.json
- Plain text: https://secwatch.observer/filing/0001493152-23-037344.txt

## Key facts
- Governance Changes
  Notable Labs, Ltd.: Amendments to the Amended and Restated Articles of Association to effect a reverse share split, increase registered share capital, change company name, and modify quorum requirements (effective 2023-10-16).
  - Change: charter amendment
  - Effective: 2023-10-16
  source text: On October 16, 2023, immediately prior to the closing of the Merger, the Company filed an amendment to the Articles with the Israeli Registrar of Companies reflecting the Reverse Share Split (including an increase in par value to NIS 0.35 per Ordinary Share), the Share Capital Increase (such that the Company has 34,285,714 authorized Ordinary Shares and NIS 12,000,000 of registered share capital) and the Name Change.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1603207/000149315223037344/0001493152-23-037344-index.htm
- M&A Transactions
  Notable Labs, Ltd. underwent a change of control involving Notable Labs, Inc. (closed 2023-10-16).
  - Action: change of control
  - Counterparty: Notable Labs, Inc.
  - Closing: 2023-10-16
  source text: On October 16, 2023, Notable Labs, Ltd., formerly known as "Vascular Biogenics Ltd." (the "Company" or "VBL"), completed its business combination with Notable Labs, Inc. ("Notable") and Vibrant Merger Sub, Inc., a wholly-owned subsidiary of the Company ("Merger Sub") in accordance with the terms of the Agreement and Plan of Merger, dated as of February 22, 2023 (the "Merger Agreement"), by and among the Company, Notable and Merger Sub.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1603207/000149315223037344/0001493152-23-037344-index.htm
- M&A Transactions
  Notable Labs, Ltd. completed a disposition involving Immunewalk Therapeutics Inc. for an upfront cash payment of $250,000 to the Company at the closing and additional payments of up to $4.75 million upon the achievement of clinical and commercial (closed 2023-10-16).
  - Action: disposition
  - Counterparty: Immunewalk Therapeutics Inc.
  - Consideration: an upfront cash payment of $250,000 to the Company at the closing and additional payments of up to $4.75 million upon the achievement of clinical and commercial
  - Closing: 2023-10-16
  source text: of October 1, 2023, between the Company and Immunewalk (the “Asset Purchase Agreement”). Under the Asset Purchase Agreement, Immunewalk agreed to pay an upfront cash payment of $250,000 to the Company at the closing and additional payments of up to $4.75 million upon the achievement of clinical and commercial milestones by Immunewalk, its Affiliates or Licensees.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1603207/000149315223037344/0001493152-23-037344-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.